Patents Assigned to St. Jude Children's Research Hospital
  • Publication number: 20210283068
    Abstract: Compositions and methods are provided for suppressing tumors by modulating the LAP pathway. Targeting components of the LAP pathway for specific drug design can be used as n immunotherapy strategy that modulates the tumor microenvironment. It is well established that infiltrating monocytes and macrophages play a pivotal role in shaping an immunosuppressive tumor microenvironment. By modulating LAP in the innate immune cells, the function of effector T cells can be manipulated toward an effective, cytotoxic immune response that can eliminate tumor cells. Thus, methods are provided for reducing the size or number of tumor cells and for treating cancer or other cell proliferative disorders. Further provided are methods for increasing the Th1 response or increasing IFN? and/or TNF? expression in the tumor microenvironment by administering a LAP inhibitor.
    Type: Application
    Filed: April 18, 2018
    Publication date: September 16, 2021
    Applicant: St. Jude Children's Research Hospital
    Inventors: Douglas R. Green, Larissa Dias da Cunha
  • Patent number: 11116757
    Abstract: In one aspect, the invention relates to substituted 1-phenyl-3-(piperidin-4-yl)urea analogs, derivatives thereof, and related compounds, which are useful as inhibitors of the DCN1-UBC12 interaction inhibitors of DCN1-mediated cullin-RING ligase activity, methods of making same, pharmaceutical compositions comprising same, methods of treating disorders using the disclosed compounds and compositions, methods of treating disorders associated with a DCN1-UBC12 interaction dysfunction, methods of treating disorders associated with a DCN1-mediated cullin-RING ligase activity dysfunction, methods of male contraception comprising the disclosed compounds and compositions, and kits comprising the disclosed compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Grant
    Filed: November 13, 2019
    Date of Patent: September 14, 2021
    Assignees: MEMORIAL SLOAN KETTERING CANCER CENTER, ST. JUDE CHILDREN'S RESEARCH HOSPITAL
    Inventors: Jaeki Min, Daniel C. Scott, Deepak Bhasin, Brenda A. Schulman, Bhuvanesh Singh, Jared T. Hammill, R. Kiplin Guy
  • Patent number: 11103597
    Abstract: The present invention relates to nucleic acid molecules containing spacers that can be packaged into viral particles and methods of producing them. In a first aspect, the invention features a nucleic acid molecule including a first spacer (SSI); a first inverted terminal repeat (ITR1); a cloning site (CS); a second inverted terminal repeat (ITR2); and a second spacer (SS2), such as a eukaryotic spacer; operably linked to each other in a 5?-to-3? direction as: SS1-ITR1-CS-ITR2-SS2. In an embodiment, the invention features a vector comprising any of the above-described nucleic acid molecules. In another aspect, the invention features a plurality of viral particles including the nucleic acid molecule. The invention further includes a host cell including any of the above-described vectors.
    Type: Grant
    Filed: May 13, 2016
    Date of Patent: August 31, 2021
    Assignee: St. Jude Children's Research Hospital, Inc.
    Inventor: John T. Gray
  • Publication number: 20210252058
    Abstract: The application relates to a chimeric antigen receptor that targets Eph receptors and allows activation of co-stimulatory pathways. The application also relates to polynucleotides that encode the chimeric antigen receptor, vectors, and host cells comprising the chimeric antigen receptor. The application also relates to methods for preparing host cells comprising a chimeric antigen receptor in order to improve the in vivo effector function of the chimeric antigen receptor host cells.
    Type: Application
    Filed: May 17, 2019
    Publication date: August 19, 2021
    Applicants: ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC., BAYLOR COLLEGE OF MEDICINE
    Inventors: Stephen GOTTSCHALK, Brooke PRINZING, Giedre KRENCIUTE
  • Patent number: 11083725
    Abstract: The invention generally relates to methods of treating viral infections using known drugs and pharmaceutical compositions comprising same. More specifically, the disclosed methods are useful for the treatment of viral infections that are enveloped viruses. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Grant
    Filed: October 16, 2015
    Date of Patent: August 10, 2021
    Assignee: ST. JUDE CHILDREN'S RESEARCH HOSPITAL
    Inventors: Heather S. Smallwood, Marie Morfouace, Martine F. Roussel, Paul G. Thomas
  • Publication number: 20210230545
    Abstract: Provided herein are methods and compositions for modulating T-cell activity by incubating a CD8 T cell with a signal 3 cytokine, such as IL-12. Incubation of naïve CD8 T cells, particularly, with a signal 3 cytokine can acquire long-lived memory associated gene expression characteristic of the stem cell memory subset of CD8 T cells. Further, incubation with signal 3 cytokines can induce changes to the epigenetic profile of naïve CD8 T cells that are more characteristic of bona fide Tscm cells than in vitro generated cells using traditional differentiation protocols. On account of epigenetic profiles being preserved during in vivo homeostasis, signal 3 cytokines such as IL-12 can be used to engineer a T cell population with the desired epigenetic profile that maintains effector functions and proliferative capacity.
    Type: Application
    Filed: July 8, 2019
    Publication date: July 29, 2021
    Applicant: St. Jude Children's Research Hospital
    Inventors: Caitlin Zebley, Hossam Abdelsamed, Benjamin Youngblood
  • Patent number: 11028051
    Abstract: In one aspect, compounds and compositions that modulate a bromodomain and methods of making and using same are disclosed. The disclosed compounds and compositions can be useful for disorders associated with inhibition of a bromodomain such as, for example, cancer. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Grant
    Filed: December 12, 2017
    Date of Patent: June 8, 2021
    Assignee: St. Jude Children's Research Hospital
    Inventors: R. Kip Guy, P. Jake Slavish, William Robert Shadrick, Brandon M. Young, Vincent A. Boyd, Nagakumar Bharatham, Jeanine E. Price, Anang Shelat
  • Patent number: 11020430
    Abstract: This disclosure relates to the genetic modification of DNMT3A gene in immune cells. In certain embodiments, the modified immune cells may be used in adoptive T cells therapies to enhance immune responses against cancer or chronic infections. In certain embodiments, the disclosure relates to deleting, changing, or inserting nucleotides within the DNMT3A gene in immune cells, e.g., human CD8 T cells, such that the DNMT3A gene product does not function for methylation. In certain embodiments, modification of the DNMT3A gene provides an improvement in antigen-specific T cells functions and/or an enhancement of the longevity of the cells.
    Type: Grant
    Filed: November 4, 2016
    Date of Patent: June 1, 2021
    Assignees: Emory University, St. Jude Children's Research Hospital, Inc.
    Inventors: Rafi Ahmed, Benjamin Youngblood
  • Publication number: 20210155690
    Abstract: Compositions and methods are provided for blocking Tim4 on the surface of myeloid cells in order to treat and prevent cancer in a subject. Blocking Tim4 on the surface of myeloid cells can restore anti-tumor immunity and reduce the uptake of apoptotic cells. Further, by administering an anti-Tim4 antibody, the pro-inflammatory anti-tumor response can be increased. Accordingly, methods for reducing the uptake of apoptotic cells and methods for increasing anti-tumor immunity are provided herein. The present disclosure further describes a method for producing monoclonal antibodies that bind Tim4 on the surface of myeloid cells. The anti-Tim4 antibodies can further be selected for their ability to inhibit engulfment of dead or dying cells, to elicit the production of inflammatory cytokines, and to restrict the growth of tumors.
    Type: Application
    Filed: April 9, 2019
    Publication date: May 27, 2021
    Applicant: St. Jude Children's Research Hospital
    Inventors: Douglas R. Green, Larissa Dias da Cunha
  • Publication number: 20210115404
    Abstract: The invention provides a chimeric receptor comprising NKG2D, DAP10 and CD3 zeta. Also disclosed is a composition comprising this chimeric receptor and methods for making and using it to enhance the cytotoxicity and antitumor capacity of NK cells. The invention also encompansses methods for use of NKG2D-DAP10-CD3 zeta polypeptides, vectors and cells in methods for treating cancer and other proliferative disorders, as well as infectious diseases.
    Type: Application
    Filed: October 9, 2020
    Publication date: April 22, 2021
    Applicants: St. Jude Children's Research Hospital, Inc., National University of Singapore
    Inventors: Dario CAMPANA, Yu-Hsiang Chang
  • Publication number: 20210069172
    Abstract: In one aspect, the invention relates to substituted 1-phenyl-3-(piperidin-4-yl)urea analogs, derivatives thereof, and related compounds, which are useful as inhibitors of the DCN1-UBC12 interaction inhibitors of DCN1-mediated cullin-RING ligase activity, methods of making same, pharmaceutical compositions comprising same, methods of treating disorders using the disclosed compounds and compositions, methods of treating disorders associated with a DCN1-UBC12 interaction dysfunction, methods of treating disorders associated with a DCN1-mediated cullin-RING ligase activity dysfunction, methods of male contraception comprising the disclosed compounds and compositions, and kits comprising the disclosed compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Application
    Filed: November 13, 2019
    Publication date: March 11, 2021
    Applicants: Memorial Sloan Kettering Cancer Center, St. Jude Children's Research Hospital
    Inventors: Jaeki MIN, Daniel C. SCOTT, Deepak BHASIN, Brenda A. SCHULMAN, Bhuvanesh SINGH, Jared T. HAMMILL, R. Kiplin GUY
  • Patent number: 10934354
    Abstract: Combinations of anti-cancer antibodies and inhibitory antibodies to CD223 overcome immune suppression in cancer patients. The inhibitory antibodies may be generated in an animal by injection of fragments of CD223. Antibodies may be monoclonal antibodies or single chain antibodies or humanized antibodies.
    Type: Grant
    Filed: March 30, 2018
    Date of Patent: March 2, 2021
    Assignees: The Johns Hopkins University, St. Jude's Children's Research Hospital, Inc.
    Inventors: Drew M. Pardoll, Ching-Tai Huang, Jonathan Powell, Charles G. Drake, Dario A. Vignali, Creg J. Workman
  • Patent number: 10920272
    Abstract: The invention relates to a high-throughput method for characterizing the genome-wide activity of editing nucleases in vitro.
    Type: Grant
    Filed: November 26, 2019
    Date of Patent: February 16, 2021
    Assignee: St. Jude Children's Research Hospital, Inc.
    Inventors: Shengdar Q. Tsai, Cicera R. Lazzarotto
  • Publication number: 20210030793
    Abstract: The application relates to a chimeric receptor that targets CD33 and allows activation of the co-stimulatory pathway without binding the natural ligand. The application also relates to polynucleotides that encode the chimeric receptor, vectors, and host cells comprising the chimeric receptor. The application also relates to methods for preparing host cells comprising a chimeric antigen receptor in order to improve the in vivo persistence of the chimeric antigen receptor host cells.
    Type: Application
    Filed: October 25, 2018
    Publication date: February 4, 2021
    Applicant: ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC.
    Inventors: Terrence L. GEIGER, Wenting SHENG, Carol E. OHEAR
  • Patent number: 10899734
    Abstract: The present disclosure relates to chemical compounds that modulate pantothenate kinase (PanK) activity for the treatment of metabolic disorders (such as diabetes mellitus type II), neurologic disorders (such as pantothenate kinase-associated neurodegeneration), pharmaceutical compositions containing such compounds, and their use in treatment. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Grant
    Filed: June 23, 2017
    Date of Patent: January 26, 2021
    Assignee: ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC.
    Inventors: Lalit Kumar Sharma, Richard E. Lee, Charles O. Rock, Suzanne Jackowski, Mi Kyung Yun, Chitra Subramanian, Jiuyu Liu
  • Patent number: 10894061
    Abstract: In one aspect, a method of treating a subject having or at risk of having graft-versus-host disease (GvHD) generally includes administering to the subject a plurality of myeloid-derived suppressor cells (MDSCs) effective to ameliorate at least one symptom or clinical sign of graft-versus-host disease compared to a suitable control subject. In another aspect, a method of treating a tumor in a subject generally includes administering to the subject an anti-tumor therapy and co-administering to the subject an inflammasome inciting agent in an amount effective to increase inflammasome activation of MDSCs sufficiently to reduce suppressor function of the MDSCs.
    Type: Grant
    Filed: August 5, 2016
    Date of Patent: January 19, 2021
    Assignees: Regents of the University of Minnesota, The University of North Carolina at Chapel Hill, St. Jude Children's Research Hospital, Inc.
    Inventors: Bruce R. Blazar, Brent Koehn, Peter J. Murray, Jenny P. Y. Ting, Robert Zeiser, Jeff S. Miller
  • Publication number: 20200408759
    Abstract: A method of identifying a lead or candidate compound that modulates the activity of GTPase-Activating Protein SH3 Domain-Binding Proteins (G3BP) is provided, which includes determining whether a compound modulates the interaction between the N-terminal Nuclear Transport Factor 2-like (NTF2L) domain of G3BP and FGDF peptide of ubiquitin specific protease 10 (USP10) or non-structural protein 3 (nsP3).
    Type: Application
    Filed: June 26, 2019
    Publication date: December 31, 2020
    Applicant: St. Jude Children's Research Hospital
    Inventors: J. Paul TAYLOR, Peiguo YANG, Wenwei LIN, Taosheng CHEN
  • Patent number: 10836999
    Abstract: The invention provides a chimeric receptor comprising NKG2D, DAP10 and CD3 zeta. Also disclosed is a composition comprising this chimeric receptor and methods for making and using it to enhance the cytotoxicity and antitumor capacity of NK cells. The invention also encompasses methods for use of NKG2D-DAP10-CD3 zeta polypeptides, vectors and cells in methods for treating cancer and other proliferative disorders, as well as infectious diseases.
    Type: Grant
    Filed: December 28, 2017
    Date of Patent: November 17, 2020
    Assignees: ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC., NATIONAL UNIVERSITY OF SINGAPORE
    Inventors: Dario Campana, Yu-Hsiang Chang
  • Patent number: 10829737
    Abstract: The invention provides a chimeric receptor comprising NKG2D, DAP10 and CD3 zeta. Also disclosed is a composition comprising this chimeric receptor and methods for making and using it to enhance the cytotoxicity and antitumor capacity of NK cells. The invention also encompasses methods for use of NKG2D-DAP10-CD3 zeta polypeptides, vectors and cells in methods for treating cancer and other proliferative disorders, as well as infectious diseases.
    Type: Grant
    Filed: December 28, 2017
    Date of Patent: November 10, 2020
    Assignees: ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC., NATIONAL UNIVERSITY OF SINGAPORE
    Inventors: Dario Campana, Yu-Hsiang Chang
  • Patent number: 10822377
    Abstract: In one aspect, the invention relates to substituted urea depsipeptide analogs, derivatives thereof, and related compounds, which are useful as activators the ClpP endopeptidease; synthesis methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating infectious disease using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Grant
    Filed: September 30, 2019
    Date of Patent: November 3, 2020
    Assignee: St. Jude Children's Research Hospital
    Inventors: Richard E. Lee, Ying Zhao, Liu Jiuyu